Using Iodine I 131 Metaiodobenzylguanidine to treat advanced neuroblastoma and pheochromocytoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness and safety of Iodine I 131 Metaiodobenzylguanidine (131 I-MIBG) in patients suffering from recurrent, progressive, or refractory neuroblastoma and malignant pheochromocytoma or paraganglioma. The study aims to determine how well this treatment works in patients whose tumors have not responded to standard therapies. Participants must have tumors that are MIBG-avid and evaluable on scans, and they must meet specific eligibility criteria regarding prior treatments and age. The trial is being conducted at the Memorial Sloan Kettering Cancer Center, a leading institution in cancer treatment.

Why it matters

Who can join: the full rules

Inclusion criteria for NB:

* Patients must have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines.
* Must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy.
* Patients must have MIBG-avid NB and evaluable disease on MIBG scan at time of enrollment on protocol
* Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.
* Age \>1 year
* Determination that radiation safety restrictions during therapy period can be implemented.
* Stem cells: Patients for high does must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. Patients for low dose do not require cryopreserved autologous hematopoietic stem cell product available. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells/kg.
* Minimum life expectancy of eight weeks
* Signed informed consent indicating awareness of the investigational nature of this program.

Inclusion criteria for malignant CCT:

* Patients must have the diagnosis of malignant CCT i.e. malignant pheochromocytoma or malignant paraganglioma
* Patients must have MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol
* Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.
* Age between 1 and 21 years and able to cooperate with radiation safety restrictions during therapy period
* Stem cells: Patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells/kg.
* Minimum life expectancy of eight weeks.
* Signed informed consent indicating awareness of the investigational nature of this program.

Exclusion Criteria:

* Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.
* Active serious infections not controlled by antibiotics.
* Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period.
* Inability or unwillingness to comply with radiation safety procedures or protocol requirements.

Where it's running

• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Ellen Basu, MD, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Ellen Basu, MD, PhD
• Phone: 212-639-5204

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

• Using 18F-MFBG PET/CT to evaluate neural crest tumors

  This study is testing a new imaging method using 18F-MFBG to see if it can help diagnose and better understand tumors like pheochromocytoma, paraganglioma, and neuroblastoma in patients.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Dongcheng · NCT05069220

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• Belzutifan and catecholamine metabolism in pheochromocytoma/paraganglioma

  This study tests whether Belzutifan can change how catecholamines are produced and broken down in adults with pheochromocytoma or paraganglioma.

  Recruiting Phase 2 Cambridge University Hospitals NHS Foundation Trust · Cambridge, Cambridgeshire · NCT07680205

• CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

  We’re testing whether donor-derived cytokine-induced memory-like NK cells can be safely given with dinutuximab to kids and young adults whose neuroblastoma has come back or not responded to treatment.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07635056

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.